Dec 29, 2020 / 12:00AM GMT
Craig West - BeiGene, Ltd. - Senior Director of IR
Hello, everyone, and welcome to BeiGene's 2020 NRDL Results Conference Call. My name is Craig West, and I'm the Head of Investor Relations here at BeiGene. After the presentation, we will take questions from the audience. (Operator Instructions)
As a reminder, today's call will be recorded.
I would now like to introduce your host for today's conference, Dr. Howard Liang, Chief Financial Officer and Chief Strategy Officer of BeiGene. Howard? You may begin.
Heng Liang - BeiGene, Ltd. - CFO & Chief Strategy Officer
Thank you, Craig, and welcome to all of you joining us from around the globe. On today's call, we'll discuss the inclusion of 3 of BeiGene's innovative oncology products on China's National Reimbursement Drug List or NRDL and implications to our company and in the markets we serve.
Today, our CEO, John Oyler, will start us off with an introduction to put the reimbursement listing outcomes into the context of our overall mission and strategy and our recent progress. We'll
Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call Transcript
Dec 29, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers